Hologic (HOLX) Scheduled to Post Quarterly Earnings on Thursday

Hologic (NASDAQ:HOLX) will announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.98 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. During the same period last year, the business earned $1.07 earnings per share. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Hologic Price Performance

Shares of HOLX opened at $76.71 on Thursday. Hologic has a 1-year low of $64.02 and a 1-year high of $87.88. The stock has a market cap of $18.01 billion, a PE ratio of 36.36, a P/E/G ratio of 2.58 and a beta of 1.00. The firm has a 50-day simple moving average of $75.95 and a two-hundred day simple moving average of $72.72. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18.

Insider Transactions at Hologic

In other news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HOLX shares. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. UBS Group lifted their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Wednesday, April 10th. Raymond James lifted their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.